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Hong yan Yu†, Xue feng Sun†, Yan xun Wang, Zuo jun Xu and Hui Huang*Abstract
Background: Whole-lung lavage (WLL) is classically the first-line treatment for symptomatic pulmonary alveolar
proteinosis (PAP). However, some patients require multiple WLLs because of refractory nature of their PAP. In
this instance, these patients may benefit from new treatment regimens, and new therapies should be tried for
these patients.
Case presentation: We describe a 47-year-old Chinese woman who was confidently diagnosed with pulmonary
alveolar proteinosis (PAP) after bronchoalveolar lavage and transbronchial lung biopsy. The patient received four
sessions of bilateral whole lung lavage (WLL) and one session of WLL in combination with plasmapheresis, each
only producing short-term symptomatic relief. The patient was given a trial of combination therapy, which
consisted of WLL and Granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation. The patient
showed a gradual improvement in oxygenation and her daily activity, as well as a dramatic improvement in
her pulmonary CT examination.
Conclusion: Bilateral WLL, in combination with GM-CSF inhalation, may be an effective treatment option for
severe refractory PAP.
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Pulmonary alveolar proteinosis (PAP) is a rare but treat-
able disease that is characterized by the accumulation of
a periodic acid Schiff (PAS) positive lipoproteinaceous
substance in the alveoli. Idiopathic PAP (iPAP), also
known as “autoimmune pulmonary alveolar proteinosis”,
makes up 90% of all described cases [1]. Whole lung lav-
age (WLL) is the most common first-line treatment for
symptomatic iPAP. However, significant proportions of
patients require multiple WLLs, or do not respond to
WLL. Many alternatives to WLL, such as GM-CSF sup-
plementation and plasmapheresis, have been introduced.* Correspondence: pumchhh@126.com
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unless otherwise stated.However, the treatment of severe refractory cases still re-
mains a major challenge for clinicians in which combin-
ation therapy instead of monotherapy maybe a better
choice. Here we describe an adult case of severe refrac-
tory PAP successfully treated with WLL in combination
with sequential GM-CSF inhalation therapy.Case presentation
A 47 year old HAN female, with no past medical history,
presented to our clinic complaining of shortness of breath
and a productive cough with white sputum. After thor-
ough investigation, she was diagnosed with pulmonary
alveolar proteinosis. High resolution CT scan (HRCT)
of her chest demonstrated the classic PAP features of
crazy paving (Figure 1A). Her bronchoalveolar lavage fluid
(BALF) was milky in appearance, and periodic acid-SchiffThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Series of her chest CT. A. The patient’s chest CT at the time of diagnosis of PAP. Her chest CT on Sep 10th 2010 showed geographic
ground-glass opacities combined with interlobular septal thickening (crazy paving) in both lungs. B. The patient’s chest CT after one month of
the first WLL. On Oct 20th 2010, about one month after the initial WLL, her repeated chest CT showed that the ground-glass opacities were
diminished in both lungs. C. The patient’s chest CT during the the fourth refractory episode of PAP. On May 26th 2012, the patient’s chest CT
showed increased crazy paving in both lungs. D. The patient’s chest CT after the combination of WLL and 5 weeks of inhalation of GM-CSF. Her
chest CT on Jul 8th 2012 showed diminished shadows in both lungs. E. The patient’s chest CT after the combination of WLL and 15 weeks of inhalation
of GM-CSF. There was significant improvement in her repeated chest CT on Sep 17th 2012.
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an excessive pinkish protein-like substance. Hematoxylin
and eosin staining of the patient’s transbronchial lung bi-
opsy (TBLB) showed multiple alveolar spaces and bron-
chioles filled with a granular acidophilic acellular material,
which stained bright pink with PAS. Her room air arterial
blood gas analysis was consistent with type 1 respiratory
failure, but could be corrected with oxygen via nasal can-
nula (NC) at 2 L/min. Her blood chemistry panel was
normal, with a LDH of 195 U/L. Pulmonary function test-
ing revealed a restrictive pattern with impaired diffusion:
FVC 2.14 L/71.4% predicted, FEV1: 1.95 L/75.8% predicted,
FEV1/FVC 90.94%, and DLco 3.19 mmol/min/kPa/39.5%
predicted, respectively.The first bilateral sequential WLL was performed under
general anesthesia in September of 2010, which improved
her symptoms and her P(A-a)O2 substantially for about
1 year. However, in October of 2011, her cough and
exertional dyspnea returned, with a room air PaO2 of
42 mmHg. Supplemental oxygen was given at 7 L/min via
NC to help correct her severe hypoxemia. At this time a
second bilateral WLL was performed, which did not im-
prove her symptoms or hypoxia. Thus, a third WLL was
to be repeated in one month (November 2011). Three
months later, in February of 2012, the patient had a third
flare of PAP which was thought to have been triggered by
the common cold. Considering the limited efficacy of
WLL therapy, plasmapheresis was considered as a possible
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followed by 5 sessions of plasmapheresis over 2 weeks, at
an exchange volume of 2.5 L. Her clinical symptoms and
radiological manifestations improved temporally. In May
of 2012, her PAP relapsed again (Figure 1C), and O2
8-9 L/min via NC was required to maintain adequate oxy-
genation. With the approval from the Ethics Committee
of our hospital, exogenous GM-CSF inhalation was given.
Considering that patients treated with GM-CSF usually
take time to respond to therapy, we applied GM-CSF in-
halation therapy in combination with WLL. The patient
received WLL on June 1st 2012 first, and then was started
on rhGM-CSF inhalation therapy at a dosage of 150 μg
twice daily for 8 days, which was then stopped for 6 days.
This cycle was repeated every 2 weeks over the next
3 months. In her follow-up visit in September of 2012, she
showed no signs of dyspnea, and had a PaO2 of 68 mmHg
on room air, as well as a significant improvement in her
chest CT (Figure 1D, E). No substantial adverse events
were reported. Another course of GM-CSF inhalation at a
dosage of 150 μg was suggested. Again given in cycles of
once daily for 8 days, and then every 2 weeks over
6 months. Until now, the patient has had no further flares
of her PAP, and was able to take care of herself without
difficulty. The patient’s complete course of treatment has
been listed in Table 1.
Discussion
Multiple treatment options have been introduced into clin-
ical managment of PAP, including WLL, plasmapheresis,
GM-CSF supplementation, Rituximab, and lung trans-
plantation. Whole lung lavage, first introduced by RamirezTable 1 Treatment of the refractory adult PAP case (listed acc
Time Treatment choice Details
SEP 16TH, 2010 Whole lung lavage Left lung: 8 L saline flushe
Right lung: 9 L saline flush
OCT 13TH, 2011 Whole lung lavage Left lung: 5.9 L saline flush
Right lung: 7 L saline flush
NOV 16TH, 2011 Whole lung lavage Left lung: 8.0 L saline flush
Right lung: 7 L saline flush
FEB 2ND, 2012 Whole lung lavage Left lung: 8.0 L saline flush
Right lung: 8 L saline flush
FEB 8th-20th, 2012 5 sessions of
plasmapheresis therapy
Exchange volume: 2.5 L, e
two weeks.
JUNE 1ST, 2012 Whole lung lavage Left lung: 9.0 L saline flush
Right lung: 7.0 L saline flus
JUNE 2nd, 2012 GM-CSF inhalation At a dosage of 150 μg, tw
day 8, with inhalation stop
day 14, every 2 weeks for
Sep, 2012 GM-CSF inhalation At a dosage of 150 μg, on
day 8, every 2 weeks for 6
WLL, whole lung lavage; PAP, pulmonary alveolar proteinosis; GM-CSF, Granulocyte
During the WLL, we used aliquots of (600-800) ml.in 1965 [2], has long been the traditional choice of treat-
ment in PAP, and was the only therapy for many years.
Over years of practice and experience with PAP, the tech-
niques regarding WLL have improved, however no consen-
sus has yet been reached. The outcomes and efficacy of
WLL has been studied extensively by various centers. A re-
cent study by Campo et al. reported the follow up data of
44 Italian PAP patients treated with WLL from a single
center [3]. Over a two-decade period, 31/44 patients re-
quired only one WLL to maintain long term symptomatic
control, with 13/44 requiring multiple WLLs. Beccaria
et al. studied 21 idiopathic PAP patients treated with WLL,
with 18/21 requiring only one session of WLL whereas 3/
21 underwent multiple WLL for recurrent PAP. In this
study, more than 70% of patients remained relapse-free
over a 7-year follow up period [4]. Also, Shah et al. shared
their experience in treating PAP patients with WLL [5],
concluding that in their experience more than 60% of pa-
tients had a good response within two sessions of WLL.
Less than 15% of these patients required WLL every six
months to maintain their functional status, and fewer than
10% were non-responsive. In our case, the patient had a
good response for the first WLL. However, multiple ses-
sions of WLLs were subsequently required, each with a
shortened duration of effectiveness.
A GM-CSF autoantibody has been identified in PAP pa-
tients but not in healthy controls [6], indicating a potential
pathologic role in PAP pathogenesis. More interestingly,
Sakagami et al. successfully reproduced PAP in nonhuman
primates after injecting patient derived GM-CSF autoanti-
bodies into these experimental animals [7,8]. This further
suggests a direct role of GM-CSF autoantibodies in theording to timeline)
Patient response
d in, 7.5 L recycled.
ed in, 8.88 L recycled.
Good response, improvement in symptoms
and PA-a maintained throughout 1 year
ed in, 5.68 L recycled.
ed in, 6.8 L recycled.
Improved symptoms and PA-a;
ed in, 7.7 L recycled.
ed in, 6.75 L recycled.
Improved symptoms, PA-a, and pulmonary
function; good control of symptoms through
3 months.
ed in, 7.82 L recycled.
ed in, 7.71 L recycled.
Symptoms and hypoxia not improved, still
required high volume oxygen support;
very 2–3 days during
ed in, 9.33 L recycled.
hed in, 6.98 L recycled.
Good symptomatic control, with no hypoxia
and no further flare of PAP
ice daily from day 1 to
ped from day 9 to
3 months;
ce daily from day 1 to
month;
-macrophage colony-stimulating factor.
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use plasmapheresis to reduce circulating autoantibodies in
the treatment of PAP. However, the experience of applying
plamapheresis in PAP patients is still quite limited, with
data only from case-reports to evaluate its efficacy. Also,
there have been multiple conflicting conclusions amongst
them. Bonfield et al. [9] reported a PAP patient which was
unresponsive to GM-CSF treatment, and while waiting for
lung transplantation received 10 sessions of plasmapher-
esis at an exchange volume of 1.5 L. Over a 2-month
period the patient’s anti-GM-CSF titer was lowered, as
well as a substantial improvement in their oxygen satur-
ation and chest radiograph. The other case presented by
Luisetti et al. [10] however showed a more passive result.
After 10 sessions of plasmapheresis (at an exchange vol-
ume of 1.5 L) anti-GM-CSF levels were reduced by half.
However, there were no improvement of the patient’s
symptoms, chest radiographs, or pulmonary function. The
interval between repeated WLLs seemed to have been
elongated. Here in our case, 5 continuous sessions of
plasmapheresis at an exchange volume of 2.5 L had a very
small improvement in symptoms and pulmonary function.
Plasmapheresis as an alternative treatment in PAP still re-
quires more investigation.
Exogenous GM-CSF supplementation is a possible res-
cue treatment, and has thus been under extensive inves-
tigation. So far two routes of GM-CSF administration
have been introduced: inhalation and subcutaneous. In a
meta-analysis reviewing the efficacy of GM-CSF in PAP
treatment, 5 observational studies (involving 94 cases)
were examined, including 3 studies using subcutaneous
GM-CSF administration and 2 studies on GM-CSF in-
halation [11]. According to this meta-analysis, the re-
sponse rate of GM-CSF therapy ranged from 43% to
92% in different studies, and the calculated pooled re-
sponse rate by the random effects model was 58.6%
(95% CI, 42.7-72.9). Fever and local erythema at the in-
jection site were the most commonly reported complica-
tions. As the alveolar space was deemed as the putative
site of the GM-CSF signal disruption, inhalation therapy
should have better deposition with lower dosage and less
effects on the bone marrow than injection therapy. Al-
though the difference was not statistically significant, the
inhalation group had a better response rate than the
subcutaneous group (76.5%; 95% CI, 34.5-95.3 vs 48.4%;
95% CI, 33.8-63.3). The relapse rate and incidence of ad-
verse events were also lower in the inhalation group.
Thus, GM-CSF inhalation was recommended for our pa-
tient. Evidence also shows a slightly better performance
of GM-CSF inhalation therapy at a dosage of 250 μg/
day, every second week [11]. But, since the only available
formulation of GM-CSF in our hospital is 150 ug per
dose, we decided to give her GM-CSF at a dosage of
150 ug twice daily from day 1 to day 8, and repeated thisevery two weeks. It is important to note that in these trials
there was usually a lag period of 4 to 12 weeks in the
inhaled group prior to showing a clinical response [sub-
stantial P(A-a)O2 improvement (≥10 mm Hg)] [12]. In con-
clusion, GM-CSF inhalation combined with WLL maybe
used to achieve a better outcome in patients with PAP, as
is the case in the patient we previously mentioned.
Conclusion
In conclusion, until now, there have been no studies con-
ducted to evaluate the efficacy of combination therapy for
PAP. Only several case reports are available, similar to
ours. This case has demonstrated the effectiveness of com-
bination therapy for a refractory PAP case. Combination
therapy is primarily indicated, and holds promise, in refrac-
tory or unresponsive cases, and because of its scarcity, it is
hard to summarize and compare the efficacy of different
combinations. For severe refractory PAP cases, we suggest
that bilateral WLL combined with sequential GM-CSF
supplementation may be an excellent treatment option.
However, WLL and plasmapheresis in combination were
not as effective in this case. We regret that during our
management of this case, due to lack of experience of our
clinical laboratory’s ability to quantify the GM-CSF auto-
antibody, we were unable to test and monitor GM-CSF
autoantibody levels during the diagnosis and treatment of
this patient.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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